PURA - Puration CBD Business Featured Today In Goldman Small Cap Research Alert
October 02 2019 - 3:32PM
InvestorsHub NewsWire
DALLAS, TX -- October 02, 2019 -- InvestorsHub NewsWire --
Puration, Inc. (PURA) today announced that
Goldman Small Cap Research has issued an “Alert” follow-up to a
recent Research Analyst Report issued on PURA. Specifically,
on Wednesday, September 25th, 2019, Goldman Small Cap
Research issued an analyst research report with investment
recommendations (report link below). The “Alert” issued today
is a confirmation of the original investment recommendations that
highlights investment new opportunities (alert link below).
Two weeks ago, Goldman published the initial results from a CBD
Beverage Industry Survey it had conducted on behalf of a PURA
initiative to launch new CBD infused beer, coffee and tea
beverages. The trade alert today indicates the definitive
survey results and analysis will be coming next week in a further
update to be issued by Goldman
The Goldman alert today offers commentary on possible
explanations for recent PURA market activity and in so doing
highlights corresponding opportunities.
To see the full trade alert issued today, follow the link
below:
PURATION, Inc. ALERT –
October 2, 2019
To see the full Analyst Report issued last week, follow the link
below:
PURAITON, Inc. Research
Analyst Report – September 25, 2019
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any
disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024